Informed Prostate Cancer Patient Support

What to Expect and Plan for in Pluvicto Treatment: A Comprehensive Guide for Prostate Cancer Patients Special Report for the IPCSG Newsletter Major FDA Expansion Opens Treatment to More Patients On March 28, 2025, the FDA expanded approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay chemotherapy. This expanded indication approximately triples the number of patients eligible to receive Pluvicto. This groundbreaking development means that many more patients can now access this innovative treatment earlier in their disease progression, potentially before requiring chemotherapy. Understanding Pluvicto: How It Works Pluvicto is a "theranostic" medicine that combines diagnostic and therapeutic capabilities. It's a type of radiation that specif...

Revolutionary Breakthrough: Remote Robotic Surgery Brings World-Class Prostate Cancer Care Across Continents A comprehensive update for the Informed Prostate Cancer Support Group Newsletter The Dawn of Transcontinental Surgery The field of prostate cancer treatment has witnessed a revolutionary milestone with the successful completion of multiple remote robotic surgeries using 5G networks and advanced robotic systems. This breakthrough technology promises to democratize access to world-class surgical expertise, potentially transforming care delivery for prostate cancer patients worldwide. The Critical Need for Remote Surgical Expertise The geographic distribution of prostate cancer patients creates a fundamental challenge in modern healthcare delivery. While prostate cancer affects men globally, highly skilled robotic surgeons capable of performing complex procedures are concentrated in major urban medical centers, often thousands of miles away from patients who need the...